Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Olipass Corporation is active in the Biotechnology & Pharmaceuticals sector with 1 pending office action currently on file. The prosecution of this portfolio is handled by a distinct examiner within 1 distinct art unit. This structure indicates that the company's current patent office interactions are concentrated in a single area of expertise.
The busiest examiner for the portfolio is SHIN, DANA H, who is responsible for the pending office action. Given that the total count of pending office actions is limited, this examiner manages the full extent of the company's active prosecution. The use of a distinct art unit reflects a specialized technical focus for the pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIN, DANA H | 1 | 26.9% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16333855 | SCN9A ANTISENSE OLIGONUCLEOTIDES | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16333855 | SCN9A ANTISENSE OLIGONUCLEOTIDES | SHIN, DANA H | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16333855 | SCN9A ANTISENSE OLIGONUCLEOTIDES | SHIN, DANA H | 1635 | §112DP | Non-Final OA | — | Pending | Mar 15, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOlipass Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dana H Shin has the most, with 1 of Olipass Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
